Travere therapeutics to present abstracts at the society for inherited metabolic disorders 43rd annual meeting and the genetic metabolic dieticians international conference 2022

San diego, april 06, 2022 (globe newswire) -- travere therapeutics, inc. (nasdaq: tvtx) today announced that the company will present data from the ongoing phase 1/2 compose study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (hcu), at the society for inherited metabolic disorders (simd) 43rd annual meeting, and the 2022 genetic metabolic dieticians international (gmdi) conference. in december 2021, the company announced positive topline results from the compose study. the company and its collaborators will also present real-world evidence from metabolic centers of excellence on current challenges in the dietary management of classical hcu.
TVTX Ratings Summary
TVTX Quant Ranking